Literature DB >> 5844004

Complex formation between basic antibiotics and deoxyribonucleic acid in human pulmonary secretions.

J L Potter, L W Matthews, S Spector, J Lemm.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1965        PMID： 5844004

Source DB:  PubMed          Journal:  Pediatrics        ISSN： 0031-4005            Impact factor:   7.124


× No keyword cloud information.
  12 in total

1.  Chelation of Membrane-Bound Cations by Extracellular DNA Activates the Type VI Secretion System in Pseudomonas aeruginosa.

Authors:  Mike Wilton; Megan J Q Wong; Le Tang; Xiaoye Liang; Richard Moore; Michael D Parkins; Shawn Lewenza; Tao G Dong
Journal:  Infect Immun       Date:  2016-07-21       Impact factor: 3.441

Review 2.  The role of recombinant human DNase in the treatment of patients with cystic fibrosis: many promises, more problems.

Authors:  M S Zach
Journal:  Thorax       Date:  1996-07       Impact factor: 9.139

3.  rhDNase in cystic fibrosis.

Authors:  S P Range; A J Knox
Journal:  Thorax       Date:  1995-04       Impact factor: 9.139

4.  Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum.

Authors:  S Shak; D J Capon; R Hellmiss; S A Marsters; C L Baker
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

5.  Studies on the absorption, distribution, metabolism, and excretion of propionylmaridomycin in rats.

Authors:  T Matsuzawa; T Kondo; Y Kita
Journal:  Antimicrob Agents Chemother       Date:  1974-12       Impact factor: 5.191

6.  Eradication of mucoid Pseudomonas aeruginosa with fluid liposome-encapsulated tobramycin in an animal model of chronic pulmonary infection.

Authors:  C Beaulac; S Clément-Major; J Hawari; J Lagacé
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

Review 7.  Pharmacokinetic optimisation of antibacterial treatment in patients with cystic fibrosis. Current practice and suggestions for future directions.

Authors:  D J Touw; A A Vinks; J W Mouton; A M Horrevorts
Journal:  Clin Pharmacokinet       Date:  1998-12       Impact factor: 6.447

8.  Influence of pulmonary surfactant on in vitro bactericidal activities of amoxicillin, ceftazidime, and tobramycin.

Authors:  A van 't Veen; J W Mouton; D Gommers; J A Kluytmans; P Dekkers; B Lachmann
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

9.  Macromolecular mechanisms of sputum inhibition of tobramycin activity.

Authors:  B E Hunt; A Weber; A Berger; B Ramsey; A L Smith
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

10.  Activity and interactions of liposomal antibiotics in presence of polyanions and sputum of patients with cystic fibrosis.

Authors:  Misagh Alipour; Zacharias E Suntres; Majed Halwani; Ali O Azghani; Abdelwahab Omri
Journal:  PLoS One       Date:  2009-05-28       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.